Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||THOR-707 + unspecified PD-1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|THOR-707||THOR707|THOR 707||THOR-707 is a pegylated recombinant version of IL-2 that binds IL2beta, but does not bind to IL-2 alpha, potentially resulting in activation and tumor infiltration of CD8-positive T cells without proliferation of CD4-positive immune cells (Annals of Oncology (2019) 30 (suppl_5): v475-v532).|
|unspecified PD-1 antibody||Experimental PD-1 antibody||PD-L1/PD-1 antibody 65|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04009681||Phase Ib/II||THOR-707 + unspecified PD-L1 antibody THOR-707 + unspecified PD-1 antibody THOR-707 THOR-707 + unspecified CTLA4 antibody||A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)||Recruiting|